Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace

Shots: Raviv Pryluk, CEO and Co-Founder of PhaseV, in a stimulating conversation with PharmaShots, sheds light on the company’s recent partnership with 9xchange Biopharma The partnership aims to bring Phase V’s proprietary machine learning (ML) technology to ecosystem members, enabling them, to retrospectively analyze and optimally design and execute advanced clinical studies Raviv highlights the…

BySaurabh ChaubeyApril 23, 2024

INSIGHTS+

Disease of the Month – Duchenne Muscular Dystrophy (DMD)

Shots: The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved For the April edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Duchenne Muscular Dystrophy,…

BySaurabh ChaubeyApril 17, 2024

VIEWPOINTS

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Shots: Following the roll-out of high throughput discovery proteomics services, Mo Jain, Founder and CEO of Sapient engages in a stimulating conversation with PharmaShots Unlike conventional mass spectrometry-based proteomics methodologies in the market, Sapient’s Discovery Proteomics Services leverage the nanoparticle enrichment technology to measure more proteins and PTMs within the plasma proteome While highlighting Sapient’s…

BySaurabh ChaubeyApril 16, 2024

VIEWPOINTS

Bayer at ASCO GU: Neal Shore Speaking about Nubeqa with PharmaShots

Shots: At ASCO GU, Bayer presented new data from its Oncology portfolio. The analysis revolved around NUBEQA (darolutamide), which is currently approved in the US in combination with docetaxel for the treatment of mHSPC and nmCRPC in adults Neal Shore in conversation with PharmaShots initiated the discussion by familiarizing our audience with the ARASENS P-III…

BySaurabh ChaubeyApril 10, 2024

THOUGHTSPOT

Your Guide to Conference Coverage in the Healthcare Industry

Shots: An ocean of knowledge, an aggregation of thought leaders, and an assembly of pharma enthusiasts like us, healthcare Conferences are turning out to be the cornerstone of ideas, learning, and most importantly, a budding spot for networking with like-minded people Conference coverage can be a convoluted task and requires immense planning before, at, and…

BySaurabh ChaubeyApril 9, 2024

EVENTS

Reuters Events: Pharma Europe 2024

Align Purpose Unleash Innovation Unlock Healthcare Pharma’s role within the healthcare system is weakening. Increased demand, economic strains, suffocating regulatory change and a widening access gap is impacting future pipelines and commercial innovations reaching patients. Siloed functions too often compete with each other instead of complement each other, failing to rally behind a common purpose.…

BySaurabh ChaubeyApril 8, 2024

VIEWPOINTS

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Shots: Following the strategic collaboration with the Sheffield Institute for Translational Neuroscience (SITraN), Metabolon’s scientific strategic director Kari Wong, engages in an illuminating conversation with PharmaShots The collaboration aims to enhance the understanding of ALS and motor neuron disease (MND) by integrating a comprehensive biomarker approach to provide better diagnostics and therapeutics for these challenging…

BySaurabh ChaubeyApril 8, 2024

VIEWPOINTS

Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots

Shots: Ofer Gonen, CEO at MediWound, in conversation with PharmaShots, sheds light on recent funding from the US Department of Defence to further develop NexoBrid for the US Army NexoBrid an FDA-approved enzymatic therapy to treat severe burns is jointly developed by Vericel and received US FDA approval in Dec’22 MediWound secured an additional $6.7M…

BySaurabh ChaubeyApril 4, 2024

VIEWPOINTS

A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah

Shots: Transformative combination therapies add wonder to oncology therapeutics now and then. Dr. Ahsan Arozullah, in another engaging conversation with PharmaShots, talks about Padcev + Keytruda therapy for adult patients suffering from locally advanced or metastatic urothelial cancer (la/mUC) Ahsan shares insights from the P-III (EV-302) trial based on which the FDA accepted Padcev +…

BySaurabh ChaubeyApril 2, 2024

Announcements

Celebrate the festival of colors with PharmaShots!

Shots: Holi, the festival of colors, fills our lives and hearts with vibrance, enthusiasm, and ecstasy. Holi remains an important festival in the Hindu traditions and is celebrated with great zeal in the Indian subcontinent The day holds a degree of paramount importance in people’s lives in India and is often treated as the day…

BySaurabh ChaubeyMarch 22, 2024

Saurabh Chaubey

Technology Infusion: Raviv Pryluk Sheds Light on PhaseV’s Recent Collaboration with 9xchange Biopharma Marketplace

Disease of the Month – Duchenne Muscular Dystrophy (DMD)

Expanding Services: Mo Jain Sheds Light on Sapient’s Recently Launched Discovery Proteomics Services

Bayer at ASCO GU: Neal Shore Speaking about Nubeqa with PharmaShots

Your Guide to Conference Coverage in the Healthcare Industry

Reuters Events: Pharma Europe 2024

Exploring Beyond: Kari Wong Sheds Light on Metabolon’s Strategic Collaboration with SITraN

Fund Secured: MediWounds’ CEO Ofer Gonen in Conversation with PharmaShots

A New Hope in Bladder Cancer Combination Therapy: PharmaShots in Conversation with Ahsan Arozullah

Celebrate the festival of colors with PharmaShots!

Contact US

OUR INFORMATION

FOLLOW US